•Arterial
events are a major cause of death in cancer patients with venous
thrombosis.
•Arterial
events occur early after venous thrombosis in cancer patients.
•The risk of
arterial events should be considered in this clinical setting.
Abstract
Background
Venous
thromboembolism is common in patients with malignancies, affecting up
to 10% of this patient population. The association between arterial
ischemic events and venous thromboembolism also has been established.
However, the influence of arterial ischemic events on outcomes in
cancer patients with venous thromboembolism has not been fully
determined.
Methods
The current study
analyzed clinical characteristics, time course, risk factors,
incidence and severity of venous thromboembolism recurrences,
arterial ischemic events and major bleeding in 5717 patients with
active cancer and venous thromboembolism recruited into RIETE
(multi-center prospective registry of patients with objectively
confirmed venous thromboembolism).
Results
During the
anticoagulation course (median 7.3 months), 499 (8.7%) patients
developed venous thromboembolism recurrences, 63 (1.1%) developed
arterial events, and 346 (6.1%) suffered from major bleeding.
Overall, major bleeding and arterial events appeared earlier (median
35 and 36 days, respectively) than venous thromboembolism recurrences
(median 97 days). Thirty-day mortality rates after each event were:
20% after recurrent pulmonary embolism, 13% after recurrent deep vein
thrombosis, 41% after major bleeding, 40% after myocardial
infarction, 64% after ischemic stroke, and 83% after lower limb
amputation. Bleeding was the leading cause of death (67 fatal
bleeds), whereas cumulative mortality due to arterial ischemic events
(n = 27) was similar to that related to pulmonary embolism
recurrences (n = 26).
Conclusions
In this study,
arterial ischemic events and major bleeding appeared early after
venous thromboembolism in patients with active cancer and were among
frequent causes of their deaths. The risk and severity of arterial
events need to be considered in this clinical setting.
No comments:
Post a Comment